166 related articles for article (PubMed ID: 37599908)
1. Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory mantle cell lymphoma (CITADEL-205): a phase 2 study.
Zinzani PL; Trněný M; Ribrag V; Zilioli VR; Walewski J; Christensen JH; Delwail V; Rodriguez G; Venugopal P; Coleman M; Dartigeas C; Patti C; Pane F; Jurczak W; Taszner M; Paneesha S; Zheng F; DeMarini DJ; Jiang W; Gilmartin A; Mehta A
EClinicalMedicine; 2023 Aug; 62():102131. PubMed ID: 37599908
[TBL] [Abstract][Full Text] [Related]
2. Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory follicular lymphoma (CITADEL-203): a phase 2 study.
Trněný M; Avigdor A; McKinney MS; Paneesha S; Wahlin BE; Hrom JS; Cunningham D; Morley N; Canales M; Bastos-Oreiro M; Belada D; Devizzi L; Zheng F; DeMarini DJ; Jiang W; Jiang P; Lynch RC
EClinicalMedicine; 2023 Sep; 63():102130. PubMed ID: 37662520
[TBL] [Abstract][Full Text] [Related]
3. A phase 2 study of the PI3Kδ inhibitor parsaclisib in relapsed and refractory marginal zone lymphoma (CITADEL-204).
Phillips TJ; Avigdor A; Gurion R; Patti C; Corradini P; Tani M; Mehta A; Lossos IS; Zinzani PL; Thieblemont C; Jurczak W; Zheng F; Rappold E; Zhao W; Jiang P; Johnson P
Blood Adv; 2024 Feb; 8(4):867-877. PubMed ID: 38113459
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of parsaclisib in combination with obinutuzumab and bendamustine in patients with relapsed or refractory follicular lymphoma (CITADEL-102): A phase 1 study.
Hamadani M; Coleman M; Boccia R; Duras J; Hutchings M; Zinzani PL; Cordoba R; Oreiro MB; Williams V; Liu H; Stouffs M; Langmuir P; Sancho JM
Hematol Oncol; 2023 Dec; 41(5):848-857. PubMed ID: 37496298
[TBL] [Abstract][Full Text] [Related]
5. Phase 2 study of parsaclisib (INCB050465), a highly selective, next-generation PI3Kδ inhibitor, in relapsed or refractory diffuse large B-cell lymphoma (CITADEL-202).
Coleman M; Belada D; Casasnovas RO; Gressin R; Lee HP; Mehta A; Munoz J; Verhoef G; Corrado C; DeMarini DJ; Zhao W; Li J; Fay K
Leuk Lymphoma; 2021 Feb; 62(2):368-376. PubMed ID: 33140664
[TBL] [Abstract][Full Text] [Related]
6. Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies.
Forero-Torres A; Ramchandren R; Yacoub A; Wertheim MS; Edenfield WJ; Caimi P; Gutierrez M; Akard L; Escobar C; Call J; Persky D; Iyer S; DeMarini DJ; Zhou L; Chen X; Dawkins F; Phillips TJ
Blood; 2019 Apr; 133(16):1742-1752. PubMed ID: 30803990
[TBL] [Abstract][Full Text] [Related]
7. Parsaclisib in Japanese patients with relapsed or refractory B-cell lymphoma (CITADEL-111): A phase Ib study.
Fukuhara N; Suehiro Y; Kato H; Kusumoto S; Coronado C; Rappold E; Zhao W; Li J; Gilmartin A; Izutsu K
Cancer Sci; 2022 May; 113(5):1702-1711. PubMed ID: 35201656
[TBL] [Abstract][Full Text] [Related]
8. BRUIN MCL-321: phase III study of pirtobrutinib versus investigator choice of BTK inhibitor in BTK inhibitor naive mantle cell lymphoma.
Eyre TA; Shah NN; Dreyling M; Jurczak W; Wang Y; Cheah CY; Song Y; Gandhi M; Chay C; Sharman J; Andorsky DJ; Messersmith HM; Ruppert AS; Muthig VA; Ito R; Wang ML
Future Oncol; 2022 Nov; 18(36):3961-3969. PubMed ID: 36377973
[TBL] [Abstract][Full Text] [Related]
9. Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma.
Wang ML; Jurczak W; Zinzani PL; Eyre TA; Cheah CY; Ujjani CS; Koh Y; Izutsu K; Gerson JN; Flinn I; Tessoulin B; Alencar AJ; Ma S; Lewis D; Lech-Maranda E; Rhodes J; Patel K; Maddocks K; Lamanna N; Wang Y; Tam CS; Munir T; Nagai H; Hernandez-Ilizaliturri F; Kumar A; Fenske TS; Seymour JF; Zelenetz AD; Nair B; Tsai DE; Balbas M; Walgren RA; Abada P; Wang C; Zhao J; Mato AR; Shah NN
J Clin Oncol; 2023 Aug; 41(24):3988-3997. PubMed ID: 37192437
[TBL] [Abstract][Full Text] [Related]
10. Parsaclisib Is a Next-Generation Phosphoinositide 3-Kinase
Shin N; Stubbs M; Koblish H; Yue EW; Soloviev M; Douty B; Wang KH; Wang Q; Gao M; Feldman P; Yang G; Hall L; Hansbury M; O'Connor S; Leffet L; Collins R; Katiyar K; He X; Waeltz P; Collier P; Lu J; Li YL; Li Y; Liu PCC; Burn T; Covington M; Diamond S; Shuey D; Roberts A; Yeleswaram S; Hollis G; Metcalf B; Yao W; Huber R; Combs A; Newton R; Scherle P
J Pharmacol Exp Ther; 2020 Jul; 374(1):211-222. PubMed ID: 32345620
[TBL] [Abstract][Full Text] [Related]
11. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
Younes A; Berdeja JG; Patel MR; Flinn I; Gerecitano JF; Neelapu SS; Kelly KR; Copeland AR; Akins A; Clancy MS; Gong L; Wang J; Ma A; Viner JL; Oki Y
Lancet Oncol; 2016 May; 17(5):622-31. PubMed ID: 27049457
[TBL] [Abstract][Full Text] [Related]
12. Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis of the Mantle Cell Lymphoma Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless Design Study.
Wang M; Siddiqi T; Gordon LI; Kamdar M; Lunning M; Hirayama AV; Abramson JS; Arnason J; Ghosh N; Mehta A; Andreadis C; Solomon SR; Kostic A; Dehner C; Espinola R; Peng L; Ogasawara K; Chattin A; Eliason L; Palomba ML
J Clin Oncol; 2024 Apr; 42(10):1146-1157. PubMed ID: 38072625
[TBL] [Abstract][Full Text] [Related]
13. Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study.
Davids MS; Kim HT; Nicotra A; Savell A; Francoeur K; Hellman JM; Bazemore J; Miskin HP; Sportelli P; Stampleman L; Maegawa R; Rueter J; Boruchov AM; Arnason JE; Jacobson CA; Jacobsen ED; Fisher DC; Brown JR;
Lancet Haematol; 2019 Jan; 6(1):e38-e47. PubMed ID: 30558987
[TBL] [Abstract][Full Text] [Related]
14. Pirtobrutinib: A novel non-covalent BTK inhibitor for the treatment of adults with relapsed/refractory mantle cell lymphoma.
Davis DD; Ohana Z; Pham HM
J Oncol Pharm Pract; 2024 Jan; 30(1):182-188. PubMed ID: 38043933
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the cardiac safety of parsaclisib, a selective PI3Kδ inhibitor, in patients with previously treated B-cell malignancies: Results from the CITADEL-101 study.
Li J; Gong X; Liu X; Liu X; Szeto K; Chen X
Pharmacol Res Perspect; 2024 Apr; 12(2):e1165. PubMed ID: 38407508
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of parsaclisib in combination with rituximab, bendamustine + rituximab, or ibrutinib in patients with previously treated B-cell lymphoma: analysis of a phase 1 dose-finding study (CITADEL‑112).
Sancho JM; Abrisqueta P; Kumar A; Cordoba R; Tani M; Langmuir P; Rappold E; Liu T; Lopez-Guillermo A
Leuk Lymphoma; 2024 Apr; ():1-11. PubMed ID: 38598516
[TBL] [Abstract][Full Text] [Related]
17. Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review study.
Hess G; Dreyling M; Oberic L; Gine E; Zinzani PL; Linton K; Vilmar A; Jerkeman M; Chen JMH; Ohler A; Stilgenbauer S; Thieblemont C; Lambert J; Zilioli VR; Sancho JM; Jiménez-Ubieto A; Fischer L; Eyre TA; Keeping S; Park JE; Wu JJ; Siddiqi R; Reitan J; Wade S; Salles G
Br J Haematol; 2023 Aug; 202(4):749-759. PubMed ID: 36257914
[TBL] [Abstract][Full Text] [Related]
18. Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study.
Burris HA; Flinn IW; Patel MR; Fenske TS; Deng C; Brander DM; Gutierrez M; Essell JH; Kuhn JG; Miskin HP; Sportelli P; Weiss MS; Vakkalanka S; Savona MR; O'Connor OA
Lancet Oncol; 2018 Apr; 19(4):486-496. PubMed ID: 29475723
[TBL] [Abstract][Full Text] [Related]
19. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
20. Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trial.
Pagel JM; Soumerai JD; Reddy N; Jagadeesh D; Stathis A; Asch A; Salman H; Kenkre VP; Iasonos A; Llorin-Sangalang J; Li J; Zelenetz AD
Lancet Oncol; 2022 Aug; 23(8):1021-1030. PubMed ID: 35835137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
